News

Under the alliance agreement, at least eight additional generic drug products will be developed by Epic Pharma and Epic Investments (collectively Epic) at Elite’s facility with the intent

Pursuant to the terms of the agreement, the two companies will develop and market new products based on Bio-Rad’s surface-enhanced laser desorption/ionization (SELDI) technology in combination with Bruker’s

During the 18-month term of the equity financing commitment, Arena may sell newly issued registered shares of its common stock to Azimuth Opportunity at a pre-negotiated discount to

“After having achieved my goal of successfully identifying and acquiring a FDA cleared, CLIA waived product that offers CLX the opportunity to become market leader in an important

US-based medical device company Cook has announced that as part of its global effort to protect its extensive intellectual property portfolio, it will appeal promptly an initial ruling

Canada-based pharmaceutical company Quest PharmaTech has formed a strategic alliance with IntelligentNano, a spin-off company from the Canadian National Research Council’s National Institute for Nanotechnology. As part of

CytRx, a biopharmaceutical company, has reported that its molecular chaperone amplifying drug candidate iroxanadine has been shown to be effective in protecting against diabetic peripheral neuropathy in animals.

American Bio Medica, a biotechnology company, has received notification from the US Patent & Trademark office that it will be granted two new patents; one for its oral

BioDelivery Sciences International, a specialty pharmaceutical company, has announced preliminary results from a Phase I study assessing two new formulations of the opioid analgesic buprenorphine utilizing the company’s